Target intelligence / Profile preview

Porcine circovirus type 2 capsid protein (PCV2 Cap)

Target
PCV2 Cap
Molecular classification
Viral structural protein, Capsid protein
01

Overview

The Porcine circovirus type 2 (PCV2) capsid protein, encoded by the ORF2 gene, is the sole structural component of the PCV2 virion and the primary target for the host's protective immune response (UniProt P0C6V4). It self-assembles into virus-like particles (VLPs) that display critical neutralizing epitopes on their surface, particularly within the loops connecting the beta-strands of the jelly-roll fold. These epitopes are essential for binding to host cell receptors such as heparan sulfate proteoglycans and facilitating viral entry into porcine cells.

In the context of porcine circovirus associated disease (PCVAD), this protein is the central focus of preventive veterinary medicine, serving as the active antigen in most commercial subunit vaccines like Ingelvac Circoflex. These vaccines aim to elicit neutralizing antibodies that block viral attachment and replication, thereby reducing clinical symptoms and viral shedding in swine populations. However, the high mutation rate of the PCV2 genome leads to significant antigenic drift, particularly in the surface-exposed loops of the capsid protein, posing a continuous challenge for vaccine efficacy and necessitating the development of multi-genotype or chimeric VLP-based therapeutics.

Other names
ORF2 proteinPCV2 capsid antigenPorcine circovirus 2 Cap proteinPCV2 structural proteinCapsid protein CP
02

Mechanism of action

Induction of humoral and cellular immune responses, specifically neutralizing antibodies that block viral attachment to host cell receptors (such as heparan sulfate) and inhibit viral entry into host macrophages and lymphocytes.

03

Biological functions

Viral attachmentViral entryViral assemblyGenome packagingImmune response inductionNuclear localization
04

Disease associations

Porcine circovirus associated disease (PCVAD)Postweaning multisystemic wasting syndrome (PMWS)Porcine dermatitis and nephropathy syndrome (PDNS)Infection
05

Safety considerations

Antigenic variation leading to vaccine escapeGenotype shifting (e.g., PCV2a to PCV2b/2d)Potential for vaccine-associated enhanced diseaseIncomplete cross-protection between genotypes
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

PCV2-specific neutralizing antibody titerSerum PCV2 DNA loadORF2-specific IgG levelsVLP-specific T-cell response

Beyond the preview

Go deeper on Porcine circovirus type 2 capsid protein (PCV2 Cap).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Porcine circovirus type 2 capsid protein (PCV2 Cap).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call